Health Surveillance Unit, Unión de Mutuas, 12004 Castellón de la Plana, Spain.
Department of Medicine, Universitat Jaume I, 12071 Castellón de la Plana, Spain.
Int J Environ Res Public Health. 2023 Jan 29;20(3):2388. doi: 10.3390/ijerph20032388.
The aim of this study was to evaluate, through a survey, the opinion of primary care (PC) physicians on the magnitude of dyslipidemia and its degree of control in their clinical practice.
An ecological study was carried out, in which the physicians were invited to participate by means of an online letter. Data were collected at a single timepoint and were based only on the experience, knowledge, and routine clinical practice of the participating physician.
A total of 300 physicians answered the questionnaire and estimated the prevalence of dyslipidemia between 2% and 80%. They estimated that 23.5% of their patients were high-risk, 18.2% were very high-risk, and 14.4% had recurrent events in the last 2 years. The PC physicians considered that 61.5% of their patients achieved the targets set. The participants fixed the presence of side-effects to statins at 14%. The statin that was considered safest with regard to side-effects was rosuvastatin (69%).
PC physicians in Spain perceive that the CVR of their patients is high. This, together with the overestimation of the degree of control of LDL-C, could justify the inertia in the treatment of lipids. Moreover, they perceive that one-sixth of the patients treated with statins have side-effects.
本研究旨在通过调查评估初级保健（PC）医生对其临床实践中血脂异常程度及其控制程度的看法。
进行了一项生态学研究，通过在线信函邀请医生参与。数据仅在单次收集，基于参与医生的经验、知识和常规临床实践。
共有 300 名医生回答了问卷，并估计血脂异常的患病率在 2%至 80%之间。他们估计 23.5%的患者为高危，18.2%为极高危，14.4%在过去 2 年内有复发事件。PC 医生认为 61.5%的患者达到了设定的目标。参与者将他汀类药物的副作用固定在 14%。关于副作用，认为最安全的他汀类药物是瑞舒伐他汀（69%）。
西班牙的 PC 医生认为他们的患者的 CVR 很高。这与 LDL-C 控制程度的高估相结合，可能解释了对脂质治疗的惰性。此外，他们认为接受他汀类药物治疗的患者中有六分之一存在副作用。
